Noven Pharmaceuticals Revenue and Competitors

The Crossings, FL USA

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Noven Pharmaceuticals's estimated annual revenue is currently $211.7M per year.(i)
  • Noven Pharmaceuticals's estimated revenue per employee is $197,438

Employee Data

  • Noven Pharmaceuticals has 1072 Employees.(i)
  • Noven Pharmaceuticals grew their employee count by 4% last year.

Noven Pharmaceuticals's People

NameTitleEmail/Phone
1
Chief Research OfficerReveal Email/Phone
2
Chief Operating OfficerReveal Email/Phone
3
VP, QualityReveal Email/Phone
4
VP and CFOReveal Email/Phone
5
VP OperationsReveal Email/Phone
6
Head Marketing & SalesReveal Email/Phone
7
VP – Hisamitsu Group Strategy & PlanningReveal Email/Phone
8
VP, QA and QCReveal Email/Phone
9
Director, Sales Training and Sales Operations LogisticsReveal Email/Phone
10
Director, QA ComplianceReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$26.5M132N/AN/AN/A
#2
$10.1M5014%N/AN/A
#3
$282.6M1406N/AN/AN/A
#4
$13.9M6944%N/AN/A
#5
$11.3M564%N/AN/A
#6
$11.5M57-7%N/AN/A
#7
$211.7M10724%N/AN/A
#8
$24.1M1205%N/AN/A
#9
$7.8M39-2%N/AN/A
#10
$12.9M64-2%N/AN/A
Add Company

What Is Noven Pharmaceuticals?

Noven Pharmaceuticals, Inc. (Nasdaq: NOVN), headquartered in Miami, Florida, is a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products. Our principal growth strategy is to apply our patented DOT Matrix® transdermal technology across diverse therapeutic categories with strong industry partners. Our patches are sold in over 30 countries, and a range of new prescription patches are under development. Together with Novartis Pharmaceuticals Corporation, we own Novogyne Pharmaceuticals, a successful women’s health products company with net sales of over $100 million in 2003. Novogyne’s lead product is Vivelle Dot® (estradiol transdermal system) – the smallest estrogen patch in the world and the most dispensed estrogen patch in the U.S. With the most advanced transdermal technology on the market, we are committed to expanding the universe of transdermal therapies for the benefit of patients, industry partners and shareholders.

keywords:N/A

N/A

Total Funding

1072

Number of Employees

$211.7M

Revenue (est)

4%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Noven Pharmaceuticals News

2022-04-17 - Methylphenidate Drug Market Size And Forecast | Janssen ...

... Janssen Pharmaceuticals, NEOS Therapeutics, Rhodes Pharmaceuticals, Noven Therapeutics, Ironshore Pharmaceuticals, Lannett Company,...

2022-04-17 - Bioidentical Hormones Market Size And Forecast | Noven ...

Noven Pharmaceuticals, Novartis AG, Sottepolle, BioTE Medical, Pfizer Inc., TherapeuticsMD Inc, Bayer AG, Novo Nordisk A/S, Others.

2022-03-30 - Worldwide Transdermal Skin Patches Industry to 2027 ...

... Nitto Denko Corporation, Noven Pharmaceuticals Inc. (Hisamitsu Pharmaceutical Co. Inc.), Prosolus Inc., Samyang Holdings Corporation,...

2007-07-11 - Noven Pharma to acquire JDS Pharma for $125M

Noven Pharmaceuticals, a Miami developer of drug-patch technologies and products, agreed to acquire privately held JDS Pharmaceuticals of New York for $125 million. JDS specializes in neurological drugs, including its antidepressant Pexeva and a timed-release form of lithum for bipolar disorder. ...